Satellos Announces Share Consolidation in Connection with Proposed Nasdaq Listing

2026-01-28 - 12:20

TORONTO -- Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announces that the Company has completed a consolidation of its outstanding common shares (the “Common Shares”) on the basis of one post-consolidation Common Share for every 12 pre-consolidation Common Shares (the “Consolidation”). The Company believes that the Consolidation should permit it to qualify for a potential listing on The Nasdaq Stock Market LLC (“Nasdaq”). Read More